Jade Pulls JADE101 Phase 3 Start Into Late 2026

The Tip Desk · November 13, 2026 · 3 min read

Jade Biosciences now expects to start EVERGREEN in the fourth quarter of 2026, after a $35.1 million net loss and $475.7 million of cash as of September 30.

Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company developing therapies for autoimmune diseases, said it expects to initiate EVERGREEN, a Phase 3 registrational trial of JADE101 in IgA nephropathy, in the fourth quarter of 2026, pulling the start forward from the first half of 2027 it had previously targeted.

Chief Executive Officer Tom Frohlich said the company is preparing to start the study ahead of schedule, citing rapid execution and continued conviction in JADE101’s potential best-in-class profile. A Trial-in-Progress poster describing EVERGREEN was presented at ASN Kidney Week 2026.

The pull-forward is the quarter’s defining development. In the second-quarter update, Jade had planned to begin the registrational study in the first half of 2027, pending FDA feedback. It now frames the start as fourth-quarter 2026. Enrollment in the Phase 2 JUNIPER trial of JADE101 remains ongoing, with interim data expected in the second quarter of 2027.

Jade also said it expects to initiate a Phase 1 trial of JADE301, an anti-IFN-β monoclonal antibody for dermatomyositis, in healthy volunteers in the fourth quarter of 2026, with interim data anticipated in the second half of 2027. That timing matched the schedule first given in the second-quarter update. Preclinical data presented at the 2026 EADV Congress included selective, high-affinity binding to IFN-β and an approximately 25-day half-life after subcutaneous dosing in non-human primates.

The Phase 1 trial of JADE201, an anti-BAFF-R antibody, in rheumatoid arthritis is ongoing, with interim biomarker-rich data expected in 2027 to inform indication prioritization. Frohlich said that, alongside JADE101 and JADE201, JADE301 will give the company three clinical-stage programs heading into 2027.

Research and development expenses were $30.8 million for the three months ended September 30, 2026, an increase of $8.8 million versus the third quarter of 2025, and included $3.6 million in stock-based compensation. The company said the rise was primarily due to increased costs around chemistry, manufacturing and controls, clinical activity, and personnel-related costs and related stock-based compensation.

General and administrative expenses were $8.8 million for the same quarter, an increase of $3.4 million versus the year-ago period, and included $3.5 million in stock-based compensation. The company attributed the increase primarily to higher personnel-related costs and related stock-based compensation.

Net loss totaled $35.1 million for the three months ended September 30, 2026, compared with $25.2 million for the third quarter of 2025. The company said the increase was driven primarily by higher R&D and G&A expenses. Net loss per share attributable to common stockholders was $0.42, versus $0.48 a year earlier, on 71.8 million weighted-average common shares.

Cash, cash equivalents, and investments were $475.7 million as of September 30, 2026, versus $461 million as of June 30, 2026. Based on current operating plans, Jade said that cash is expected to fund operating expenses and capital expenditure into the fourth quarter of 2028. Interest income was $4.6 million in the quarter.

The company expanded Brad Dahms’ role and title to Chief Financial Officer and Chief Business Officer. He continues to oversee finance and investor relations and will now also lead business development and corporate strategy as Jade advances its pipeline toward multiple clinical readouts in 2027.

Jade said it sees significant opportunities in 2027 to demonstrate the differentiated profiles of its programs. The company also cautioned that the planned JADE101 Phase 3 trial may be delayed based on FDA feedback or requirements, and that interim results are not necessarily indicative of final results.